Clinical Trial Update: A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease. [Phase 2]

View source ↗

Summary

A Phase 2 randomized, double-blind, placebo-controlled trial evaluating PrimeC for mild-to-moderate Alzheimer's disease was terminated at this center, assessing…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• PrimeC

Snippet

Sponsor: NeuroSense Therapeutics Ltd. | Conditions: Alzheimer Disease | Phase 2 | Status: TERMINATED